ARA-290 (Cibinetide): The Erythropoietin Fragment That Heals Nerves Without Building Blood

What ARA-290 Actually Is

If you’ve been around peptides long enough, you know erythropoietin (EPO). Cyclists got busted with it, kidney patients use it, and the bodybuilding world has flirted with it for endurance cycles. The problem with EPO is it’s a sledgehammer — it cranks up your hematocrit, thickens your blood, and statistically increases your stroke risk if you misuse it.

What almost nobody outside academic immunology knows is that EPO has two completely separate biological jobs. Job one: tell your bone marrow to make more red blood cells. Job two: protect tissue from inflammatory damage and stimulate repair. Those two jobs run through two different receptors. The hematopoietic job uses the homodimeric EPOR receptor on bone marrow precursors. The tissue-protective job uses a heteromeric receptor — EPOR paired with the common beta receptor (βcR, CD131) — on immune cells, neurons, and endothelium.

ARA-290 is an 11-amino-acid peptide engineered to hit only the heteromeric tissue-protective receptor. Sequence: pyroglutamate-EQLERALNSS. It does not bind the hematopoietic receptor at meaningful concentrations. So you get every benefit of EPO’s anti-inflammatory and neurorestorative signaling, with zero hematocrit elevation. That’s a structural separation of effects, not a dose-dependent one — you cannot accidentally turn ARA-290 into a blood-doping agent.

Deep Biochemistry: How Cibinetide Repairs Nerves

The innate repair receptor (IRR, the EPOR/βcR heterodimer) is upregulated specifically on tissues that are stressed or damaged. Healthy resting tissue expresses very little of it. Damaged tissue lights up with it. This is the cleanest “smart drug” mechanism in peptide pharmacology — the receptor only shows up where you actually need the signaling.

When ARA-290 binds the IRR, three downstream cascades fire simultaneously:

1. JAK2/STAT signaling collapse of inflammatory drive. Activated IRR phosphorylates JAK2, which then suppresses NF-κB-driven cytokine production. TNF-α, IL-6, and IL-1β all drop. In sarcoidosis patients on cibinetide, peripheral TNF-α has dropped roughly 40–60% over 28 days of treatment in the published clinical data. This is not aspirin-level inflammation reduction — this is upstream cytokine suppression.

2. PI3K/Akt activation in neurons. The same JAK2 activation drives PI3K/Akt phosphorylation in nerve tissue, which triggers anti-apoptotic gene expression and stimulates axonal sprouting. This is the mechanism behind the small-fiber regrowth seen in diabetic neuropathy trials. Confocal corneal microscopy in ARA-290 trials has shown measurable increases in corneal nerve fiber density — that’s literal regrowth of peripheral nerves you can image.

3. eNOS upregulation in endothelium. Endothelial nitric oxide synthase increases, which improves microvascular perfusion. Diabetic neuropathy is partly a microvascular disease — the tiny capillaries feeding peripheral nerves get rarefied and the nerves starve. ARA-290 fixes the supply line at the same time it repairs the nerves themselves.

Per the Tony Huge Laws of Biochemistry Physics, ARA-290 is a textbook illustration of Law 1: governors vs accelerators. Most peptide protocols for nerve injury (BPC-157, TB-500) are pure accelerators — they push regeneration. The problem with chronic neuropathy is that TNF-α and IL-6 are the governors actively blocking repair. Push BPC-157 into a system saturated with inflammatory cytokines and you get partial response at best. ARA-290 releases the governor first by collapsing the inflammatory cytokine cascade, then the accelerator peptides actually work. Stack it correctly and you can get response in patients who failed BPC-157 monotherapy.

Natural Plus Protocol

Cibinetide is supplied as a lyophilized powder, typically reconstituted with bacteriostatic water to a 4 mg/mL concentration.

Standard dose range: 1 to 4 mg subcutaneous, daily or every other day. The published phase 2 trials in sarcoidosis-induced small fiber neuropathy used 4 mg subcutaneous daily for 28 days. Most peripheral pain users will run 2 mg daily as a sweet spot.

Cycle: 4 to 8 weeks on, then 4 weeks off to assess durability of effect. Unlike BPC-157, you’re not running this indefinitely. Once the inflammatory cascade is reset and the nerve has regrown, you stop and let the system maintain itself.

Timing: Morning subcutaneous injection, abdominal site rotation. There’s no acute performance benefit to time it pre-workout — this is a structural repair compound, not an ergogenic aid.

Co-factors to monitor: Blood glucose stays unchanged. CBC stays unchanged (this is the whole point — no hematocrit drift). Inflammatory markers (hs-CRP, ESR) typically drop within 14 days. If you have access, neurofilament light chain (NfL) is the cleanest serum biomarker of ongoing nerve damage and trends down on cibinetide.

Cycle support: Not needed. ARA-290 is functionally inert outside the IRR. No liver, kidney, or cardiac strain at therapeutic doses. No PCT required.

Stacking Recommendations

Cibinetide hits an independent receptor system from any common bodybuilding peptide. Per Law 5 (independent receptor stacking) of the Tony Huge Laws of Biochemistry Physics, you can layer it freely with the standard repair stack without diminishing returns.

Stack Compound	Pathway	Why It Synergizes
BPC-157	FAK/paxillin, VEGF, growth hormone axis	Once ARA-290 has dropped inflammatory tone, BPC-157’s pro-angiogenic and tissue-repair signaling actually penetrates. This is the gold-standard chronic injury stack.
TB-500 (Thymosin Beta-4)	Actin sequestration, cell migration	Mobilizes progenitor cells to the repair site once cibinetide has cleared the inflammatory garbage. Particularly effective for old, calcified injuries.
MOTS-c	Mitochondrial-derived peptide, AMPK activation	Energy supply to recovering nerve tissue. Peripheral nerves are absurdly mitochondria-dense and ATP-hungry during regrowth.
LL-37 or KPV (selective)	Antimicrobial / anti-inflammatory	If the underlying neuropathy has an infectious or post-viral component (small fiber neuropathy after long-COVID is the most common case in 2026), KPV adds NF-κB suppression without immune compromise.

Target Audience

This is not a “general wellness” peptide. ARA-290 is for people with a specific, identifiable nerve-driven pain or dysfunction:

• Diabetic neuropathy patients (Type 1 and Type 2): The phase 2 ARA-290 trial in T2D neuropathy showed measurable corneal nerve fiber regrowth at 28 days. If you have burning feet, allodynia, or progressive numbness on a known diabetic baseline, this is the cleanest peptide intervention available.
• Sarcoidosis with small fiber neuropathy: The original development indication. Symptom relief and HRV improvements documented.
• Post-chemo or post-radiation peripheral neuropathy: Off-label but mechanistically aligned. The CIPN (chemo-induced peripheral neuropathy) literature on EPO suggests benefit; ARA-290 is the cleaner version.
• Long-COVID small fiber neuropathy: A subset of long-COVID presents as autonomic dysfunction with biopsy-confirmed small fiber damage. This is exactly the patient population ARA-290 was built for.
• Heavy AAS users with nerve compression or pudendal neuralgia: Niche, but I’ve seen multiple cases in our community where chronic high-dose cycles produced peripheral nerve symptoms that resolved on a 6-week ARA-290 run.

Realistic Timeline

Timeframe	What to Expect
Week 1	Subjective inflammation drop. Joint stiffness eases. Pain scores typically unchanged — nerves haven’t regrown yet, but the inflammatory drive is collapsing.
Week 2–3	Sleep quality improves (lower nocturnal cytokine surges). hs-CRP drops measurably. Pain begins shifting from constant burn to intermittent.
Week 4	Confocal corneal microscopy at this point in the trial showed nerve fiber density increases. Subjectively: improved sensation in numb areas, restored proprioception.
Week 6–8	Peak structural benefit. Many users see autonomic improvements — better HRV, less postural orthostatic symptoms, improved gut motility.
Week 12 (4 weeks off-cycle)	Benefits hold in roughly 70% of responders. Non-responders typically have a structural cause (compression, stenosis) that requires mechanical intervention.

Interesting Perspectives

A few angles on cibinetide that the standard peptide YouTube circuit hasn’t caught up to:

The autonomic nervous system angle. Most discussion of ARA-290 centers on peripheral pain. The more interesting application is autonomic dysfunction. The vagal nerve has small unmyelinated fibers that are vulnerable to the same inflammatory damage as the somatic small fibers. People with POTS, idiopathic gastroparesis, or “long-COVID dysautonomia” are often dealing with vagal small-fiber injury. Cibinetide is one of the only interventions with a mechanistic case for repairing this — and a handful of patients in the long-COVID community have been quietly running it with good results.

The TBI/concussion application. The IRR is highly upregulated in injured CNS tissue. Pre-clinical TBI models show ARA-290 reduces lesion volume and improves cognitive recovery. Nobody is running this for post-concussion syndrome yet because the peptide isn’t FDA-approved and the awareness gap is wide, but mechanistically it’s a stronger TBI candidate than the current standard-of-care (which is essentially nothing).

The “EPO’s hidden second life” framing. Look at where natural EPO is expressed. It’s not just kidney. The brain, the heart, the retina, the testes, and the uterus all produce EPO locally during stress or development. None of that is for blood production — those tissues aren’t talking to bone marrow. That’s the IRR pathway, doing tissue protection. The endogenous EPO system has been doing this job for hundreds of millions of years. ARA-290 is just the pharmaceutical-grade version of a signal your body already uses.

The contrarian take on phase 3 failure. ARA-290 / cibinetide was being developed by Araim Pharmaceuticals. The phase 2b in sarcoidosis was promising, but the regulatory pathway has been slow. Many in the peptide research community read this as a regulatory and commercial issue, not a mechanism issue — neuropathy is a hard endpoint to powerfully measure in trials, and the molecule is a small peptide that’s commercially difficult to protect with patents long-term. The mechanism is solid; the business case is the bottleneck.

Cross-domain link to longevity. Chronic low-grade TNF-α elevation (“inflammaging”) is one of the strongest correlates of biological age acceleration. Anything that suppresses TNF-α at the source — without the immune compromise of monoclonal antibody anti-TNF therapy — has a longevity argument. ARA-290 is in that category. It’s not a pure longevity peptide, but the inflammation collapse it produces is exactly the signal the senolytic/inflammaging crowd is chasing.

What I’ve Seen Personally

Living in Pattaya, I’ve had a front-row seat to a lot of peptide experimentation. Two of my circle ran ARA-290 specifically for nerve issues — one for diabetic burning feet, one for post-injury pudendal neuralgia. Both responded inside 4 weeks. The diabetic was the more dramatic case — he’d already failed gabapentin, duloxetine, and a year of BPC-157 monotherapy. Adding cibinetide changed his pain scores from 7/10 to 2/10 at week 6.

This is not a vanity peptide. You don’t run it for “feeling good.” You run it when you have a specific nerve-driven problem and you need the inflammatory governor pulled off before any other repair compound can do its job.

Frequently Asked Questions

What is ARA-290?

ARA-290, also called cibinetide, is an 11-amino-acid peptide derived from the structure of erythropoietin (EPO). It activates the innate repair receptor (the EPOR/βcR heterodimer) on inflamed and damaged tissue, suppressing TNF-α and triggering peripheral nerve regrowth, without raising red blood cell count.

Will ARA-290 raise my hematocrit like EPO?

No. Cibinetide does not bind the homodimeric EPO receptor on bone marrow precursors. Hematocrit stays at baseline at every published clinical dose. This is the entire point of the molecule — tissue-protective signaling without the hematological side of EPO.

What’s the standard cibinetide dose?

Published clinical studies used 1 to 4 mg subcutaneous daily for 28 days. The most common community dose is 2 mg daily, cycled 4 to 8 weeks on with a 4-week washout. Reconstitute with bacteriostatic water and inject subcutaneously into the abdomen with a fresh insulin syringe.

Can I stack ARA-290 with BPC-157 and TB-500?

Yes — and you should, if your goal is chronic injury repair. ARA-290 hits the IRR receptor, BPC-157 hits FAK/VEGF/GH-axis pathways, and TB-500 works through actin sequestration. All three pathways are independent, so stacking gives additive benefit without diminishing returns. Cibinetide handles the inflammation; BPC-157 and TB-500 drive structural rebuild.

Who should NOT use ARA-290?

Active malignancy is a hard contraindication — IRR signaling can promote tumor cell survival in some lineages. Pregnancy and lactation are open questions due to lack of human data. If you have no clear nerve-driven symptom, you don’t need it; this is a targeted repair tool, not a general wellness peptide.

Related Reading on tonyhuge.is

• GLP-1 drugs muscle loss: Tony Huge’s Peptide Prevention Guide — broader peptide context
• MOTS-c Peptide: Mitochondrial Enhancement for Elite Athletes — primary stack partner for nerve repair energy supply
• LL-37 Peptide: Breaking Down Chronic Gut Biofilms — anti-inflammatory peptide for post-viral cases
• Selank: The Anxiolytic Nootropic Peptide for Stress and Focus — autonomic regulation pairing
• Klotho Protein: The Anti-Aging Molecule Your Kidneys Make — inflammaging context
• Tony Huge’s First law of biochemistry physics — the framework applied here